CONCORD DRUGS Financial Statement Analysis
|
||
|
The Revenues of CONCORD DRUGS have increased by 0.71% YoY .
The Earnings Per Share (EPS) of CONCORD DRUGS has decreased by -27.66 % YoY. |
||
CONCORD DRUGS Last 5 Annual Financial Results
[BOM: 538965]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|
| Revenues | ₹45 Cr | ₹45 Cr | ₹52 Cr | ₹59 Cr |
| Expenses | ₹41 Cr | ₹41 Cr | ₹48 Cr | ₹53 Cr |
| Operating Profit (Excl OI) | ₹4.14 Cr | ₹4.04 Cr | ₹4.57 Cr | ₹5.59 Cr |
| Other Income | ₹0.01 Cr | ₹0.01 Cr | ₹0.01 Cr | ₹0.10 Cr |
| Interest | ₹2.03 Cr | ₹1.87 Cr | ₹1.71 Cr | ₹1.68 Cr |
| Depreciation | ₹1.43 Cr | ₹1.56 Cr | ₹1.63 Cr | ₹1.77 Cr |
| Profit Before Tax | ₹0.69 Cr | ₹0.63 Cr | ₹1.25 Cr | ₹2.25 Cr |
| Profit After Tax | ₹0.34 Cr | ₹0.47 Cr | ₹0.99 Cr | ₹1.59 Cr |
| Consolidated Net Profit | ₹0.34 Cr | ₹0.47 Cr | ₹0.99 Cr | ₹1.59 Cr |
| Earnings Per Share (Rs) | ₹0.34 | ₹0.47 | ₹1.06 | ₹1.82 |
| PAT Margin (%) | 0.74 | 1.05 | 1.89 | 2.70 |
| ROE(%) | 0.99 | 1.45 | 3.31 | 5.62 |
| ROCE(%) | 5.19 | 4.99 | 6.32 | 8.77 |
| Total Debt/Equity(x) | 0.56 | 0.52 | 0.54 | 0.58 |
Key Financials |
||
| Market Cap | : | ₹ 99.5 Cr |
| Revenue (TTM) | : | ₹ 78.8 Cr |
| Net Profit(TTM) | : | ₹ 1.1 Cr |
| EPS (TTM) | : | ₹ 0.8 |
| P/E (TTM) | : | 94.5 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| CONCORD DRUGS | -0.3% | -6.2% | 124.7% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 7.5% | 12.8% |
| DIVIS LABORATORIES | 4.2% | 3.9% | 1.5% |
| TORRENT PHARMACEUTICALS | 4.3% | 11.2% | 42.5% |
| CIPLA | 0.4% | 5.3% | -3% |
| DR REDDYS LABORATORIES | 0.9% | 8% | 5.6% |
| MANKIND PHARMA | -0.3% | 7.9% | 8.4% |
| LUPIN | 3% | 10.8% | 27.8% |
| ZYDUS LIFESCIENCES | 3.2% | 5.8% | 16.2% |
CONCORD DRUGS Revenues
[BOM: 538965]
| Y-o-Y | 0.71 % |
| 5 Yr CAGR | -8.45 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹45 Cr | 0.71 | |
| Mar2024 | ₹45 Cr | -13.74 | |
| Mar2023 | ₹52 Cr | -11.66 | |
| Mar2022 | ₹59 Cr | - | |
CONCORD DRUGS Operating Profit
[BOM: 538965]
| Y-o-Y | 2.28 % |
| 5 Yr CAGR | -9.58 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹4.14 Cr | 2.28 | |
| Mar2024 | ₹4.04 Cr | -11.57 | |
| Mar2023 | ₹4.57 Cr | -18.25 | |
| Mar2022 | ₹5.59 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 1.56 % |
| 5 Yr CAGR | -1.24 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 9.14% | 1.56 | |
| Mar2024 | 9% | 2.51 | |
| Mar2023 | 8.78% | -7.48 | |
| Mar2022 | 9.49% | - | |
CONCORD DRUGS Profit After Tax
[BOM: 538965]
| Y-o-Y | -28.81 % |
| 5 Yr CAGR | -40.49 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.34 Cr | -28.81 | |
| Mar2024 | ₹0.47 Cr | -52.13 | |
| Mar2023 | ₹0.99 Cr | -38.14 | |
| Mar2022 | ₹1.59 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -29.52 % |
| 5 Yr CAGR | -35.04 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 0.74 % | -29.52 | |
| Mar2024 | 1.05 % | -44.44 | |
| Mar2023 | 1.89 % | -30.00 | |
| Mar2022 | 2.7 % | - | |
CONCORD DRUGS Earnings Per Share (EPS)
[BOM: 538965]
| Y-o-Y | -27.66 % |
| 5 Yr CAGR | -42.83 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.34 | -27.66 | |
| Mar2024 | ₹0.47 | -55.66 | |
| Mar2023 | ₹1.06 | -41.76 | |
| Mar2022 | ₹1.82 | - | |
CONCORD DRUGS Return on Capital Employed (ROCE)
[BOM: 538965]
| Y-o-Y | 4.01 % |
| 5 Yr CAGR | -16.04 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 5.19% | 4.01 | |
| Mar2024 | 4.99% | -21.04 | |
| Mar2023 | 6.32% | -27.94 | |
| Mar2022 | 8.77% | - | |
CONCORD DRUGS Share Price vs Sensex
| Current Share Price | : | ₹75.4 |
| Current MarketCap | : | ₹ 99.5 Cr |
| Updated EOD on | : | Jul 06,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CONCORD DRUGS | -0.3% |
-6.2% |
124.7% |
| SENSEX | 2% |
5.3% |
-6.5% |
CONCORD DRUGS related INDICES
You may also like the below Video Courses
FAQ about CONCORD DRUGS Financials
How the annual revenues of CONCORD DRUGS have changed ?
The Revenues of CONCORD DRUGS have increased by 0.71% YoY .
How the Earnings per Share (EPS) of CONCORD DRUGS have changed?
The Earnings Per Share (EPS) of CONCORD DRUGS has decreased by -27.66 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs